

PRESS RELEASE

To finance the acquisition of a manufacturer of implants for spine surgery, Implanet has signed for the fourth time a convertible bond line with its long-term financial partner, Nice & Green.

Bordeaux, Boston, January 13, 2021 – 5.45 pm CET– IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has finalized an exclusive negotiation agreement with a view to acquiring a company specialized in designing, manufacturing and selling implants for spine surgery².

The integration of this new product range within Implanet's JAZZ® platform would contribute to the creation of a comprehensive and innovative range of spine surgery products and to maintaining Implanet's position as an independent leader in band implants.

This acquisition and the financing of the Company's activity will be funded by a financing line comprising of €5 million in convertible bonds, signed with Nice & Green, the Implanet long-time financial partner since 2018. A portion of these funds will also be used to finance the new entity's operating cash requirements through 2021 and 2022, before reaching positive cash flow at the end of 2022.

FOR FURTHER INFORMATION:**Adela KORSELT****CFO - Nice & Green SA**

TEL : +41 22 361 37 95

E-MAIL : akorselt@nicengreen.ch**ABOUT IMPLANET**

Founded in 2007, Implanet is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its activity revolves around two product ranges, the latest generation JAZZ® implant, designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery, and the MADISON implant designed for first-line prosthetic knee surgery. Implanet's tried-and-tested orthopedic platform is based on product traceability.

Protected by four families of international patents, JAZZ® and MADISON have obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States, the CE mark as well as the ANVISA authorization in Brazil. Implanet employs 36 staff and recorded 2019 sales of €7.4 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, Implanet established a US subsidiary in Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris.

More information on www.implanet.com

ABOUT NICE & GREEN SA

Nice & Green SA is an independent Swiss Proprietary Equity Investment and Alternative Financing company who helps micro and small-sized listed companies to secure funding needed for their growth. Nice & Green is owned and managed by two principals and capitalizes on establishing long term financial partnership with the companies it assists. `

More information on www.nicengreen.ch.